These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 30594206)

  • 1. Clinical phenotypes and biologic treatment use in juvenile dermatomyositis-associated calcinosis.
    Orandi AB; Dharnidharka VR; Al-Hammadi N; Baszis KW;
    Pediatr Rheumatol Online J; 2018 Dec; 16(1):84. PubMed ID: 30594206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Short-Term Ultraviolet Radiation Exposure and Disease Severity in Juvenile Dermatomyositis: Results From the Childhood Arthritis and Rheumatology Research Alliance Legacy Registry.
    Neely J; Long CS; Sturrock H; Kim S;
    Arthritis Care Res (Hoboken); 2019 Dec; 71(12):1600-1605. PubMed ID: 30714338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lower extremity lipedema, upper extremity lipodystrophy and severe calcinosis complicating juvenile dermatomyositis.
    Pavlov-Dolijanovic SR; Vujasinovic Stupar NZ; Gavrilov N; Seric S
    Rheumatol Int; 2014 Nov; 34(11):1615-8. PubMed ID: 24789670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk factors associated with calcinosis of juvenile dermatomyositis.
    Sallum AM; Pivato FC; Doria-Filho U; Aikawa NE; Liphaus BL; Marie SK; Silva CA
    J Pediatr (Rio J); 2008; 84(1):68-74. PubMed ID: 18185899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment, classification and treatment of calcinosis as a complication of juvenile dermatomyositis: a survey of pediatric rheumatologists by the childhood arthritis and rheumatology research alliance (CARRA).
    Orandi AB; Baszis KW; Dharnidharka VR; Huber AM; Hoeltzel MF;
    Pediatr Rheumatol Online J; 2017 Sep; 15(1):71. PubMed ID: 28934971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of acquired lipodystrophy in juvenile-onset dermatomyositis and a gradient of severity.
    Bingham A; Mamyrova G; Rother KI; Oral E; Cochran E; Premkumar A; Kleiner D; James-Newton L; Targoff IN; Pandey JP; Carrick DM; Sebring N; O'Hanlon TP; Ruiz-Hidalgo M; Turner M; Gordon LB; Laborda J; Bauer SR; Blackshear PJ; Imundo L; Miller FW; Rider LG;
    Medicine (Baltimore); 2008 Mar; 87(2):70-86. PubMed ID: 18344805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Skin disease is more recalcitrant than muscle disease: A long-term prospective study of 184 children with juvenile dermatomyositis.
    Wang A; Morgan GA; Paller AS; Pachman LM
    J Am Acad Dermatol; 2021 Jun; 84(6):1610-1618. PubMed ID: 33359787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Juvenile dermatomyositis forty years on: Case report.
    Rego de Figueiredo I; Guerreiro Castro S; Bernardino V; Silva Nunes J; Alves P; Moraes-Fontes MF
    Neuromuscul Disord; 2018 Sep; 28(9):791-797. PubMed ID: 30064892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Race, Income, and Disease Outcomes in Juvenile Dermatomyositis.
    Phillippi K; Hoeltzel M; Byun Robinson A; Kim S;
    J Pediatr; 2017 May; 184():38-44.e1. PubMed ID: 28410093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disease activity and prognostic factors in juvenile dermatomyositis: a long-term follow-up study applying the Paediatric Rheumatology International Trials Organization criteria for inactive disease and the myositis disease activity assessment tool.
    Sanner H; Sjaastad I; Flatø B
    Rheumatology (Oxford); 2014 Sep; 53(9):1578-85. PubMed ID: 24692575
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of changes in disease activity among children with juvenile dermatomyositis enrolled in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Legacy Registry.
    Challa D; Crowson CS; Niewold TB; Reed AM;
    Clin Rheumatol; 2018 Apr; 37(4):1011-1015. PubMed ID: 29170979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sodium thiosulfate for the treatment of calcinosis secondary to juvenile dermatomyositis.
    Pagnini I; Simonini G; Giani T; Marrani E; Moretti D; Vannucci G; Cantarini L; Cimaz R
    Clin Exp Rheumatol; 2014; 32(3):408-9. PubMed ID: 24238152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biologic therapies for refractory juvenile dermatomyositis: five years of experience of the Childhood Arthritis and Rheumatology Research Alliance in North America.
    Spencer CH; Rouster-Stevens K; Gewanter H; Syverson G; Modica R; Schmidt K; Emery H; Wallace C; Grevich S; Nanda K; Zhao YD; Shenoi S; Tarvin S; Hong S; Lindsley C; Weiss JE; Passo M; Ede K; Brown A; Ardalan K; Bernal W; Stoll ML; Lang B; Carrasco R; Agaiar C; Feller L; Bukulmez H; Vehe R; Kim H; Schmeling H; Gerstbacher D; Hoeltzel M; Eberhard B; Sundel R; Kim S; Huber AM; Patwardhan A;
    Pediatr Rheumatol Online J; 2017 Jun; 15(1):50. PubMed ID: 28610606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Calcinosis in juvenile dermatomyositis: frequency, risk factors and outcome.
    Saini I; Kalaivani M; Kabra SK
    Rheumatol Int; 2016 Jul; 36(7):961-5. PubMed ID: 27007612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aggressive management of juvenile dermatomyositis results in improved outcome and decreased incidence of calcinosis.
    Fisler RE; Liang MG; Fuhlbrigge RC; Yalcindag A; Sundel RP
    J Am Acad Dermatol; 2002 Oct; 47(4):505-11. PubMed ID: 12271292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Favorable outcomes with reduced steroid use in juvenile dermatomyositis.
    Orandi AB; Fotis L; Lai J; Morris H; White AJ; French AR; Baszis KW
    Pediatr Rheumatol Online J; 2021 Aug; 19(1):127. PubMed ID: 34404425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient and physician discordance of global disease assessment in juvenile dermatomyositis: findings from the Childhood Arthritis & Rheumatology Research Alliance Legacy Registry.
    Tory H; Zurakowski D; Kim S;
    Pediatr Rheumatol Online J; 2020 Jan; 18(1):5. PubMed ID: 31941511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High frequency of calcinosis in juvenile dermatomyositis: a risk factor study.
    Clemente G; Piotto DG; Barbosa C; Peracchi OA; Len CA; Hilário MO; Terreri MT
    Rev Bras Reumatol; 2012 Aug; 52(4):549-53. PubMed ID: 22885422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Calcinosis in juvenile dermatomyositis is influenced by both anti-NXP2 autoantibody status and age at disease onset.
    Tansley SL; Betteridge ZE; Shaddick G; Gunawardena H; Arnold K; Wedderburn LR; McHugh NJ;
    Rheumatology (Oxford); 2014 Dec; 53(12):2204-8. PubMed ID: 24987158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bisphosphonates in juvenile dermatomyositis with dystrophic calcinosis.
    Tayfur AC; Topaloglu R; Gulhan B; Bilginer Y
    Mod Rheumatol; 2015 Jul; 25(4):615-20. PubMed ID: 25800510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.